about
Impaired DNA replication within progenitor cell pools promotes leukemogenesis.The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phaseExpression of the TEL-Syk fusion protein in hematopoietic stem cells leads to rapidly fatal myelofibrosis in miceAHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cellsSrc family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity.Reciprocal t(9;22) ABL/BCR fusion proteins: leukemogenic potential and effects on B cell commitment.Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics.Declining lymphoid progenitor fitness promotes aging-associated leukemogenesis.Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine modelThe Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues.Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.Targeting mutated tyrosine kinases in the therapy of myeloid leukaemias.Hypoxia-Like Signatures Induced by BCR-ABL Potentially Alter the Glutamine Uptake for Maintaining Oxidative PhosphorylationMolecular genetics of B-precursor acute lymphoblastic leukemiaRole of Dok-1 and Dok-2 in leukemia suppression.CREB is a critical regulator of normal hematopoiesis and leukemogenesis.Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1.Genomic mechanisms of p210BCR-ABL signaling: induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis.Antisense inhibition of Bcr-Abl/c-Abl synthesis promotes telomerase activity and upregulates tankyrase in human leukemia cells.Can anthocyanins improve maintenance therapy of Ph(+) acute lymphoblastic leukaemia?Production of replication-defective retrovirus by transient transfection of 293T cells.SOCS1 function in BCR-ABL mediated myeloproliferative disease is dependent on the cytokine environment.Murine retroviral bone marrow transplantation models for the study of human myeloproliferative disorders.Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway.Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.Suppression of bcr-abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic genes and cell proliferation factors (microarray study).Reduced efficacy of mesenchymal stromal cells in preventing graft-versus-host disease in an in vivo model of haploidentical bone marrow transplant with leukemia.Crk-associated substrate lymphocyte type regulates myeloid cell motility and suppresses the progression of leukemia induced by p210Bcr/Abl.
P2860
Q24816866-82353779-7C3B-451C-A456-563D47257510Q26749343-3555C213-0C37-406D-8055-B039D9A9CE05Q27303848-CB85686A-BA66-4F35-BBC8-3F118DC42DBEQ28586026-77DC6B37-F9E3-4B07-A3A5-1E1153CF19FEQ30159676-EFA723D1-A14D-4F9D-9519-168FA54B12E8Q33513975-2B446A57-74C0-42C9-8D9F-61277EFA57A7Q33899740-7CBE6F48-FC32-4455-AB8A-7EC13177DB80Q34411132-7F81079A-D090-4D4B-924A-B83DBF95CACEQ34734850-961559F0-F184-4727-BB17-6D7CF007C05DQ34750582-35FA62AE-123F-4073-A8D0-DCF6ABFB431EQ35735401-ADBC6546-A296-4840-AB91-B87D82C434A5Q35782893-3E0C2B0E-A119-4583-83FE-D061FFA12A2CQ35982752-F210199B-33F4-4CE4-9933-D06A1B00994AQ36290242-205A8ED3-A49A-43B8-B0F6-6B4EB4BD6905Q36399814-0ABB70E8-A406-4806-9464-6A97DE86E999Q36407217-F7BBE360-1B1B-4FF7-AA27-FB6683E3D2B9Q36854122-535252DF-927A-4DB0-9418-DF75184FF332Q37697852-F6CF6031-7072-4C80-A3AF-AB6C280C6740Q38340918-86A30443-F32E-4D61-BE87-A39D0303D9A4Q38342295-26B0E5E5-D9A5-4AAD-B450-65D842DD5A63Q39215315-DD9A66DD-0378-465C-8989-B3870E578687Q39920432-6FA289D0-99D1-48DE-806D-7A79E3BA6D7CQ42339101-095E2A74-C329-4381-8FAB-21EE2326356EQ42721777-095419D2-1BCB-40C0-B05E-A334BE0C1213Q43250891-962D7B5A-425F-4372-99A2-A09544F05CBFQ44851706-3667E508-2495-4F30-8C1A-F46598A8E716Q44976586-1ED49AC1-1E30-4B87-A0B1-91809EFC3700Q45852750-BB8137A8-03AC-4D71-9C4F-251D50246683Q54567366-51A658DB-3099-4472-91C6-F352D8E456FB
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Studying the pathogenesis of BCR-ABL+ leukemia in mice.
@ast
Studying the pathogenesis of BCR-ABL+ leukemia in mice.
@en
type
label
Studying the pathogenesis of BCR-ABL+ leukemia in mice.
@ast
Studying the pathogenesis of BCR-ABL+ leukemia in mice.
@en
prefLabel
Studying the pathogenesis of BCR-ABL+ leukemia in mice.
@ast
Studying the pathogenesis of BCR-ABL+ leukemia in mice.
@en
P2860
P356
P1433
P1476
Studying the pathogenesis of BCR-ABL+ leukemia in mice.
@en
P2093
Richard A Van Etten
P2860
P2888
P304
P356
10.1038/SJ.ONC.1206091
P407
P577
2002-12-01T00:00:00Z